We scan new podcasts and send you the top 5 insights daily.
Pharmaceutical sponsors typically lack commercial incentives to fund non-inferiority trials testing shorter durations or treatment cessation. Academic groups must step forward to lead discontinuation studies, such as stopping immunotherapy after stable disease, which offer significant quality-of-life benefits.
After years of treatment intensification, a new focus in metastatic hormone-sensitive prostate cancer is de-escalation. Trials like ADREAM are evaluating planned treatment interruptions for patients with excellent responses, aiming to provide 'treatment-free intervals' that improve quality of life without sacrificing efficacy.
Traditional non-inferiority trials for reducing treatment are difficult to fund and execute. A proposed paradigm shift is to use superiority trial designs, where the burden of proof is on demonstrating that a higher dose or longer duration of therapy is actually better than a de-escalated approach.
Traditional endpoints like progression-free survival (PFS) incentivize continuous treatment. The NCI group proposes "treatment-free survival," a novel metric that quantifies time spent *off* therapy. This endpoint better captures the patient experience and rewards treatments that provide durable responses after a finite course.
Immunotherapy is now inducing complete responses in a small subset of advanced HCC patients. This success presents a novel challenge, as there is no data to guide decisions on treatment duration, forcing difficult discussions about stopping therapy in patients who may be cured.
The next frontier in CSCC isn't just about new drugs, but about optimizing existing ones. A key research area is determining the minimum number of immunotherapy doses required for an optimal response—potentially just one or two—to limit toxicity, reduce treatment burden, and personalize care for high-risk patients.
Despite data supporting limited-duration immunotherapy, physicians struggle to stop treatment. Patients in complete remission often view the well-tolerated therapy as a "lifeline," creating psychological barriers to de-escalating care.
Data shows that patients who permanently stopped ipilimumab due to immune-related side effects still had exceptionally good outcomes. This gives clinicians confidence to manage toxicity by discontinuing the CTLA-4 inhibitor portion of the regimen while continuing nivolumab, without fearing a loss of efficacy.
As potent ADCs prove effective, the current paradigm of treating until disease progression is unsustainable due to cumulative toxicity. Experts urge trial designers to be "brave" and prospectively investigate optimal, fixed treatment durations sooner rather than later, shifting the goal from indefinite therapy to achieving a deep remission.
For biochemically recurrent (BCR) prostate cancer, which is often indolent, trials should not wait years to study treatment reduction. The NCI group universally agreed that de-escalation strategies—such as intermittent therapy—should be the default design from the outset, prioritizing quality of life and avoiding overtreatment.
An expert expresses a strong preference for time-limited CLL therapies over continuous maintenance treatments. The rationale is that getting patients into a deep remission and then off treatment entirely leads to a better overall experience and quality of life, even if they eventually relapse.